Bones have a remarkable potential to heal completely after fractures. However, in the presence of diseases such as type 2 diabetes mellitus (T2DM), this capacity is severely limited. This is where the project "System medicine approach for personalised bone defect treatment in patients comorbid with type 2 diabetes" (SyMBoD), funded by the German Federal Ministry of Education and Research (BMBF), comes in.
The central hypothesis in SyMBoD is that an exogenous vascular bed is required for the regeneration of endogenous tissue and thus for the improvement of the healing process. The concrete design is adapted to the specific needs of the patient. The second goal is therefore the development of a digital platform with theranostic function. This platform will support clinicians in design modelling and decision making for such a regenerative bone therapy. In order to achieve this ambitious goal, the interdisciplinary team follows a systems medicine approach.
At Fraunhofer IZI, the Protein Biomarkers Unit and Bioinformatics Unit perform the sample preparation for building the biobank, create the molecular profiles and implement the correlation of the various omics data sets. In the "SyMBoD" project team, they cooperate with research groups from Charité - Universitätsmedizin Berlin, University of Freiburg, Technical University of Munich (TUM), and Genevention GmbH.
Prof. Dr. Stefan Kalkhof
Worm infections still present a major health-related challenge, especially in tropical and sub-tropical regions. According to statistics published by the Centers for Disease Control and Prevention in 2013, more than 700 million people around the globe are affected by hookworm infections alone, which cause up to 60 000 deaths per year. The infection is transmitted upon coming into contact with water or soil that has been contaminated with feces, which means that it mainly affects rural populations. The infection can be treated effectively with albendazole or mebendazole. The diagnostic methods used at present (Kato Katz, MiniFLOTAC, McMaster) require trained staff and a suitable diagnostic infrastructure, which is why many infections are not diagnosed until very late.
The aim of the international collaboration project “WormShield”, which sees the Protein Biomarker Unit collaborate with the company BioScientia (Poland), Cayetano Heredia University (Peru) and Dr. Hugo Mendoza Pediatric Hospital (Dominican Republic), is to improve the diagnosis of hookworm infections in an everyday clinical setting by developing a quick, specific, sensitive, robust and easy-to-use lateral-flow assay. This test is then to be rolled out around the world as a point-of-care diagnostic tool.
The project is being funded by the EU as part of the EU-LAC Health initiative to promote cooperative health research with states from Latin America and the Caribbean.
Prof. Dr. Stefan Kalkhof
The frequency of newly developed food allergies (incidence) is increasing worldwide. At the same time, a rise in non-conventional food ingredients – particularly plant-based ingredients – has been registered, following the modern trend of resource-conscious food. This trend has also been noted by European directives with the purpose of making consumers aware of the risk of allergies as well as protecting them from the consequences of allergies (LMIV). As a result, the demand for reliable methods to analyze allergenic ingredients as well as for the technology to reduce allergenic ingredients has grown significantly over the past few years.
The "LowAllergen" project and its follow-up project, "FoodAllergen", are concerned with plant-based allergenic food ingredients. One part of the project is geared towards changing proteins to the extent that their allergenic potential is decreased. The requirements for this are innovative technologies for modifying proteins which are developed in our partner institute Fraunhofer IVV. As part of the “Food Allergen” project, the Protein Biomarker Unit is responsible for developing antibody-based test systems which enable a quantitative analysis of allergenic ingredients and reveal any remaining allergenic potential after applying allergen-reducing procedures. Using soy as an example, in the "LowAllergen" project, a decrease of allergenic components could be observed as a result of applying certain microorganisms in fermentation processes and hydrolysis using high pressure. In the "FoodAllergen" project, the processes and analytical methods will be expanded to other plant-based protein ingredients to implement technologies for modifying allergens as well as analytical methods for detecting successful reduction of allergens as soon as possible.
Dr. Jörg Lehmann
In the field of ‘Biomarker-based veterinary diagnostics’ specific and sensitive diagnostic techniques based on immunological biomarkers are going to be developed for cattle. Screening tests verifying biomarkers are particularly appropriate to detect sick animals within the herds prior the occurrence of clinical symptoms. Positively diagnosed animals could supply veterinary examination in a targeting manner. Potentially, this approach could result in a medium-term increase in economic efficiency. Because animals’ health and well-being are closely related the development of biomarker tests contributes considerably to the principles of animals’ and consumers’ welfare.
In the project ‚On-Farm-Recording_Breeding‘ supported by the (former) Federal Ministry of Food, Agriculture and Consumer Protection, the Department of Therapy Validation has identified and characterized different biomarkers for health monitoring in cattle. A patent application submitted in 2015 is aimed at an international patent protection. The best performing biomarker candidates are currently under pre-commercial development at different stages. The final steps to reach marketability will be done in close collaboration with our industrial partners. A substantial benefit for the optimal diagnostic value is expected from the combined detection of biomarker through multiplex analysis. Together with partners in veterinary medicine, livestock breeding farms, and diagnostics industries we aim at the development of user-friendly products that will be well-accepted by farmers. Moreover, we seek to offer innovative product concepts that will suit the needs of a future-compliant agriculture.
The diagnostic assay for the detection of haptoglobin, a major acute-phase protein in cattle, is currently at the last stage of pre-commercial development, i.e. clinical validation. For the development of diagnostic assays for further interesting biomarker candidates we are searching for granting opportunities.
Dr. Anke Hoffmann, Dr. Jörg Lehmann